DNLI
Denali Therapeutics Inc.
Healthcare — Biotechnology
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Price History
Fundamentals
| Market Cap | $4.12B |
| P/E Ratio (TTM) | - |
| Forward P/E | -10.48 |
| EPS (TTM) | $-2.88 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -49.59% |
| Debt/Equity | 4.32 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $33.93 |
| Analysts | 15 |
| Next Earnings | Aug 6, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 89.3 |
| Beta | 1.01 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $26.36 |
| 52-Week Low | $12.58 |
| 50-Day Avg | $20.79 |
| 200-Day Avg | $18.78 |
| Avg Volume | $1.80M |
| Volume | $1.17M |
Performance Analysis
NEUTRALDNLI presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:06 UTC
Back to Screener Export Report